Active Ingredient History
Treosulfan, sold under the brand name Trecondi, is a medication given to people before they have a bone marrow transplant from a donor known as allogeneic hematopoietic stem cell transplantation. It is used as a 'conditioning' treatment to clear the bone marrow and make room for the transplanted bone marrow cells, which can then produce healthy blood cells. It is used together with another medicine called fludarabine in adults and children from one month of age with blood cancers as well as in adults with other severe disorders requiring a bone marrow transplant. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Allogeneic Cells (Phase 2)
Anemia (Phase 2)
Anemia, Diamond-Blackfan (Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Failure Disorders (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Graft vs Host Disease (Phase 2)
Hematologic Neoplasms (Phase 2)
Hemoglobinopathies (Phase 2)
Hemoglobinuria, Paroxysmal (Phase 2)
Hodgkin Disease (Phase 2)
Leukemia (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Leukemia, Prolymphocytic (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 3)
Metabolism, Inborn Errors (Phase 2)
Multiple Myeloma (Phase 2)
Mycoses (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 2)
Nijmegen Breakage Syndrome (Phase 2)
Ovarian Neoplasms (Phase 3)
Primary Immunodeficiency Diseases (Phase 2)
Prostatic Neoplasms (Phase 2)
Sarcoma, Ewing (Phase 3)
Shwachman-Diamond Syndrome (Phase 2)
Transplantation, Homologous (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue